The US Food and Drug Administration (FDA) today approved the Zoetis vaccine once a month for the treatment of pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints of older cats.
Osteoarthritis breaks down the protective cartilage that protects the joints, leading to increased friction that causes pain and reduced movement.
The drug, Solensia, with the active ingredient frunevetmab, is the first veterinary monoclonal antibody approved by the FDA.
Monoclonal antibodies make copies of antibodies made by the body to fight an infection.
Solensia was approved based on two efficacy studies that used cat evaluations by veterinarians and owners’ ratings of pre- and post-treatment pet movements.
The most common side effects seen in cats from Solensia treatment included vomiting, diarrhea, injection pain and itchy skin.